INSULIN-STIMULATED RELEASE OF D-CHIRO-INOSITOL-CONTAINING INOSITOLPHOSPHOGLYCAN

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 胰岛素的某些作用是由肌醇磷酸聚糖(IPG)介体介导的。在多囊卵巢综合征(PCOS)患者中，含有D-环肌醇(DCI)的IPG介质释放不足可能是导致胰岛素抵抗的原因之一。在此之前，我们证明口服DCI可以改善多囊卵巢综合征患者的排卵和代谢参数。然而，口服DCI是否介导了PCOS妇女DCI-IPG介体释放的增加和胰岛素敏感性的改善尚不清楚。我们对11名患有多囊卵巢综合征的妇女进行了DCI补充剂和安慰剂的随机对照试验，她们在相隔6周的两个时间点进行了评估。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Some actions of insulin are mediated by inositolphosphoglycan (IPG) mediators. Deficient release of a putative D-chiro-inositol-containing (DCI) IPG mediator may contribute to insulin resistance in women with polycystic ovary syndrome (PCOS). Previously, we demonstrated that oral DCI supplementation improved ovulation and metabolic parameters in women with PCOS. However, whether oral DCI mediates an increase in the release of the DCI-IPG mediator and an improvement in insulin sensitivity in women with PCOS is unknown. We conducted a randomized controlled trial of DCI supplementation vs placebo in 11 women with PCOS who were assessed at 2 time points 6 weeks apart.